Tag Archives: NASDAQ:REPH

Oppenheimer Sticks to Their Buy Rating for Recro Pharma (REPH)

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Recro Pharma (NASDAQ: REPH), with a price target of $18. The company’s shares closed yesterday at $8.07. Gershell observed: “Yesterday’s announcement by REPH that it plans

Oppenheimer Thinks Recro Pharma’s Stock is Going to Recover

Oppenheimer analyst Leland Gershell maintained a Buy rating on Recro Pharma (NASDAQ: REPH) today and set a price target of $18. The company’s shares closed yesterday at $5.66, close to its 52-week low of $4.78. Gershell said: “Recro Pharma’s 2Q18

Analysts Offer Insights on Healthcare Companies: Recro Pharma (NASDAQ: REPH) and Strongbridge Biopharma Plc (NASDAQ: SBBP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Recro Pharma (NASDAQ: REPH) and Strongbridge Biopharma Plc (NASDAQ: SBBP) with bullish sentiments. Recro Pharma (NASDAQ: REPH) Oppenheimer analyst Derek Archila maintained

Recro Pharma Gets a Buy Rating from Oppenheimer

In a report released today, Derek Archila from Oppenheimer maintained a Buy rating on Recro Pharma (NASDAQ: REPH). The company’s shares closed yesterday at $11.07. According to TipRanks.com, Archila is a 3-star analyst with an average return of 5.3% and

A Director at Recro Pharma is Exercising Options

Today, a Director at Recro Pharma, Michael Berelowitz, exercised options of Recro Pharma for $78.3K. This is Berelowitz’s first transaction since reporting a Sell transaction on ORMP back in December 2015 Based on Recro Pharma’s latest earnings report for the

Oppenheimer Sticks to Their Buy Rating for Recro Pharma

In a report released today, Derek Archila from Oppenheimer maintained a Buy rating on Recro Pharma (NASDAQ: REPH), with a price target of $19. The company’s shares opened today at $9.01. Archila wrote: “This morning, we attended REPH’s analyst day,